The major horse allergen Equ c 1 contains one immunodominant region of T cell epitopes

Clinical and Experimental Allergy

Volumn 37, Issue 6, 2007, Pages 939-947

  Immonen, A ^a   Kinnunen, T ^a   Sirven, P ^b   Taivainen, A ^c   Houitte, D ^b   Perasaari J ^d   Narvanen A ^a   Saarelainen, S ^a   Rytkonen Nissinen M ^a   Maillere, B ^b   Virtanen, T ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b CEA SACLAY   (France)

^c KUOPIO UNIVERSITY HOSPITAL   (Finland)

^d FINNISH RED CROSS BLOOD SERVICE   (Finland)

Author keywords

Allergens; MHC peptide interactions; Peptide immunotherapy; Proliferation; T cells

Indexed keywords

ALLERGEN; AMINO ACID; BOS D 2 ALLERGEN; CAN F 1 ALLERGEN; EPITOPE; EQU C 1 ALLERGEN; HORSE ALLERGEN; LEUKOCYTE ANTIGEN; LIPOCALIN; UNCLASSIFIED DRUG;

ALLERGIC REACTION; AMINO ACID SEQUENCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL STIMULATION; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; COW; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOTHERAPY; MONONUCLEAR CELL; NUCLEOTIDE SEQUENCE; PEPTIDE SYNTHESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE;

ALLERGENS; ANIMALS; CATTLE; CELL LINE; CROSS REACTIONS; DOGS; EPITOPES, T-LYMPHOCYTE; GLYCOPROTEINS; HISTOCOMPATIBILITY ANTIGENS CLASS II; HORSES; HUMANS; HYPERSENSITIVITY; LEUKOCYTES, MONONUCLEAR; MALE; PEPTIDES; PROTEIN BINDING;

EID: 34447503925     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2007.02722.x     Document Type: Article

References (45)

1. Virtanen T, Mäntyjärvi R. Mammalian allergens. In : Lockey RF, Bukantz SC, Bousquet J, eds. Allergens and allergen immunotherapy. New York : Marcel Dekker, 2004 297 317.
2. Åkerstrom B, Flower DR, Salier JP. Lipocalins: unity in diversity. Biochim Biophys Acta 2000 1482 : 1 8.
3. Flower DR, North AC, Sansom CE. The lipocalin protein family: structural and sequence overview. Biochim Biophys Acta 2000 1482 : 9 24.
4. Tutluoglu B, Atis S, Anakkaya AN, Altug E, Tosun GA, Yaman M. Sensitization to horse hair, symptoms and lung function in grooms. Clin Exp Allergy 2002 32 : 1170 3.
5. Roberts G, Lack G. Horse allergy in children. BMJ 2000 321 : 286 7.
6. Kim JL, Elfman L, Mi Y, Johansson M, Smedje G, Norback D. Current asthma and respiratory symptoms among pupils in relation to dietary factors and allergens in the school environment. Indoor Air 2005 15 : 170 82.
7. Rönmark E, Perzanowski M, Platts-Mills T, Lundback B. Different sensitization profile for asthma, rhinitis, and eczema among 7-8-year-old children: report from the obstructive lung disease in northern Sweden studies. Pediatr Allergy Immunol 2003 14 : 91 9.
8. Larche M, Wraith DC. Peptide-based therapeutic vaccines for allergic and autoimmune diseases. Nat Med 2005 11 : S69 76.
9. Maguire P, Nicodemus C, Robinson D, Aaronson D, Umetsu DT. The safety and efficacy of ALLERVAX CAT in cat allergic patients. Clin Immunol 1999 93 : 222 31.
10. Müller U, Akdis CA, Fricker M et al. Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. J Allergy Clin Immunol 1998 101 : 747 54.
11. Saarelainen S, Taivainen A, Rytkönen-Nissinen M et al. Assessment of recombinant dog allergens can f 1 and can f 2 for the diagnosis of dog allergy. Clin Exp Allergy 2004 34 : 1576 82.
12. Rautiainen J, Auriola S, Rouvinen J et al. Molecular and crystal properties of bos d 2, an allergenic protein of the lipocalin family. Biochem Biophys Res Commun 1998 247 : 746 50.
13. Immonen A, Farci S, Taivainen A et al. T cell epitope-containing peptides of the major dog allergen can f 1 as candidates for allergen immunotherapy. J Immunol 2005 175 : 3614 20.
14. Zeiler T, Mäntyjärvi R, Rautiainen J et al. T cell epitopes of a lipocalin allergen colocalize with the conserved regions of the molecule. J Immunol 1999 162 : 1415 22.
15. Texier C, Pouvelle S, Busson M et al. HLA-DR restricted peptide candidates for bee venom immunotherapy. J Immunol 2000 164 : 3177 84.
16. Texier C, Pouvelle-Moratille S, Busson M, Charron D, Menez A, Maillere B. Complementarity and redundancy of the binding specificity of HLA-DRB1, -DRB3, -DRB4 and -DRB5 molecules. Eur J Immunol 2001 31 : 1837 46.
17. Castelli FA, Buhot C, Sanson A et al. HLA-DP4, the most frequent HLA II molecule, defines a new supertype of peptide-binding specificity. J Immunol 2002 169 : 6928 34.
18. Gregoire C, Rosinski-Chupin I, Rabillon J, Alzari PM, David B, Dandeu JP. cDNA cloning and sequencing reveal the major horse allergen equ c1 to be a glycoprotein member of the lipocalin superfamily. J Biol Chem 1996 271 : 32951 9.
19. Konieczny A, Morgenstern JP, Bizinkauskas CB et al. The major dog allergens, can f 1 and can f 2, are salivary lipocalin proteins: cloning and immunological characterization of the recombinant forms. Immunology 1997 92 : 577 86.
20. Mäntyjärvi R, Parkkinen S, Rytkönen M et al. Complementary DNA cloning of the predominant allergen of bovine dander: a new member in the lipocalin family. J Allergy Clin Immunol 1996 97 : 1297 303.
21. Falquet L, Pagni M, Bucher P et al. The PROSITE database, its status in 2002. Nucleic Acids Res 2002 30 : 235 8.
22. Singh H, Raghava GP. ProPred: prediction of HLA-DR binding sites. Bioinformatics 2001 17 : 1236 7.
23. Kinnunen T, Taivainen A, Partanen J et al. The DR4-DQ8 haplotype and a specific T cell receptor vb T cell subset are associated with abscence of allergy to can f 1. Clin Exp Allergy 2005 35 : 797 803.
24. Jeal H, Draper A, Harris J, Taylor AN, Cullinan P, Jones M. Determination of the T cell epitopes of the lipocalin allergen, rat n 1. Clin Exp Allergy 2004 34 : 1919 25.
25. Bielekova B, Sung MH, Kadom N, Simon R, McFarland H, Martin R. Expansion and functional relevance of high-avidity myelin-specific CD4+ T cells in multiple sclerosis. J Immunol 2004 172 : 3893 904.
26. Virtanen T, Zeiler T, Rautiainen J, Mäntyjärvi R. Allergy to lipocalin: a consequence of misguided T-cell recognition of self and nonself? Immunol Today 1999 20 : 398 400.
27. Adorini L, Appella E, Doria G, Nagy ZA. Mechanisms influencing the immunodominance of T cell determinants. J Exp Med 1988 168 : 2091 104.
28. Gammon G, Sercarz E. How some T cells escape tolerance induction. Nature 1989 342 : 183 5.
29. Fairchild PJ, Wraith DC. Lowering the tone: mechanisms of immunodominance among epitopes with low affinity for MHC. Immunol Today 1996 17 : 80 5.
30. Geluk A, van Meijgaarden KE, Schloot NC, Drijfhout JW, Ottenhoff TH, Roep BO. HLA-DR binding analysis of peptides from islet antigens in IDDM. Diabetes 1998 47 : 1594 601.
31. Phelps RG, Jones V, Turner AN, Rees AJ. Properties of HLA class II molecules divergently associated with Goodpasture's disease. Int Immunol 2000 12 : 1135 43.
32. Sospedra M, Muraro PA, Stefanova I et al. Redundancy in antigen-presenting function of the HLA-DR and -DQ molecules in the multiple sclerosis-associated HLA-DR2 haplotype. J Immunol 2006 176 : 1951 61.
33. Kedl RM, Schaefer BC, Kappler JW, Marrack P. T cells down-modulate peptide-MHC complexes on APCs in vivo. Nat Immunol 2002 3 : 27 32.
34. Kinnunen T, Kwok WW, Närvänen A et al. Immunomodulatory potential of heteroclitic analogs of the dominant T-cell epitope of lipocalin allergen bos d 2 on specific T cells. Int Immunol 2005 17 : 1573 81.
35. Hoyne GF, O'Hehir RE, Wraith DC, Thomas WR, Lamb JR. Inhibition of T cell and antibody responses to house dust mite allergen by inhalation of the dominant T cell epitope in naive and sensitized mice. J Exp Med 1993 178 : 1783 8.
36. Zuleger CL, Gao X, Burger MS, Chu Q, Payne LG, Chen D. Peptide induces CD4(+) CD25+ and IL-10+ T cells and protection in airway allergy models. Vaccine 2005 23 : 3181 6.
37. Kinnunen T, Buhot C, Närvänen A et al. The immunodominant epitope of lipocalin allergen bos d 2 is suboptimal for human T cells. Eur J Immunol 2003 33 : 1717 26.
38. Reijonen H, Mallone R, Heninger AK et al. GAD65-specific CD4+ T-cells with high antigen avidity are prevalent in peripheral blood of patients with type 1 diabetes. Diabetes 2004 53 : 1987 94.
39. Gebe JA, Falk BA, Rock KA et al. Low-avidity recognition by CD4+ T cells directed to self-antigens. Eur J Immunol 2003 33 : 1409 17.
40. Counsell CM, Bond JF, Ohman JL Jr., Greenstein JL, Garman RD. Definition of the human T-cell epitopes of fel d 1, the major allergen of the domestic cat. J Allergy Clin Immunol 1996 98 : 884 94.
41. Kämmerer R, Chvatchko Y, Kettner A, Dufour N, Corradin G, Spertini F. Modulation of T-cell response to phospholipase A2 and phospholipase A2-derived peptides by conventional bee venom immunotherapy. J Allergy Clin Immunol 1997 100 : 96 103.
42. Fritsch R, Bohle B, Vollmann U et al. Bet v 1, the major birch pollen allergen, and Mal d 1, the major apple allergen, cross-react at the level of allergen-specific T helper cells. J Allergy Clin Immunol 1998 102 : 679 86.
43. Ling EM, Smith T, Nguyen XD et al. Relation of CD4+ CD25+ regulatory T-cell suppression of allergen-driven T-cell activation to atopic status and expression of allergic disease. Lancet 2004 363 : 608 15.
44. Grindebacke H, Wing K, Andersson AC, Suri-Payer E, Rak S, Rudin A. Defective suppression of Th2 cytokines by CD4CD25 regulatory T cells in birch allergics during birch pollen season. Clin Exp Allergy 2004 34 : 1364 72.
45. Bullens DM, Van Den Keybus C, Dilissen E, Kasran A, Ceuppens JL. Allergen-specific T cells from birch-pollen-allergic patients and healthy controls differ in T helper 2 cytokine and in interleukin-10 production. Clin Exp Allergy 2004 34 : 879 87.